Related Experiment Video

Updated: Jul 14, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Developmental status of young infants with congenital heart disease

Yukimi Hirose1, Fukiko Ichida, Yoshihiro Oshima

  • 1Department of Pediatric Nursing, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan. hhyuki@yamanishi-ken.ac.jp

Pediatrics International : Official Journal of the Japan Pediatric Society
|June 26, 2007
PubMed

Insights

Infants with congenital heart disease (CHD) experiencing poor weight gain (<10 g/day) and whose mothers do not recognize developmental delays are at higher risk. Early identification of growth issues and maternal awareness are crucial for supporting infant development.

Area of Science:

  • Pediatrics
  • Developmental Biology
  • Cardiology

Background:

  • Congenital heart disease (CHD) impacts young infants' physical and psychosocial development.
  • Understanding developmental trajectories is vital for targeted interventions in infants with CHD.

Purpose of the Study:

  • To examine developmental status in infants with CHD.
  • To identify factors associated with developmental delays in this population.

Main Methods:

  • Japanese Denver Developmental Screening Test administered to 75 infants (3-5 months).
  • Mothers completed questionnaires on perceived child development.
  • Comparative analysis of infants with and without developmental delay, including clinical factors and maternal recognition.

Main Results:

  • 18.7% of infants exhibited developmental delay.
  • Weight gain (standard weight-2SD), Kaup index, and maternal recognition of development were associated with delay.
  • Infants gaining <10 g/day showed significantly more delay than those gaining >20 g/day.

Conclusions:

  • Infant growth, particularly weight gain, is strongly linked to developmental status in CHD.
  • Weight gain below 10 g/day is a critical indicator for developmental delay.
  • Maternal recognition of developmental delay is also a significant factor.
Abstract

More Related Videos

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods08:28

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Published on: March 10, 2020

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Related Concept Videos

Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...